Genmab — Oktober 2018
-
@KB. Mener det er rimlig relevant at kigge paa hvilken PE markedet tidligere har vaeret villige til at betale for Genmab og det er omkring PE 80. Saa hvis Genmab kan skabe samme interesse om casen som da vi var i pe 80 ser jeg ingen grund til at i ikke skulle handle til PE 80 igen.
-
Tror ikke det var nuværende scenarie han mente
https://borsen.dk/nyheder/virksomheder/artikel/1/366992/jan_van_de_winkel_genmab_staar_foran_to_utrolige_aar_med_darzalex.html -
https://borsen.dk/nyheder/opinion/artikel/11/209421/artikel.html Mon ikke Genmab kunne nyde godt af teorien i denne artikel.
-
God morgen.

Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind